Usana Health Sciences Inc: Form 10-Q for the period ended Jun 28, 2025
Filed with the SEC on Aug 5, 2025 and accepted by EDGAR at Aug 5, 2025, 16:50 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-28. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-03-30 to 2025-06-28 | $235.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2024-12-29 to 2025-06-28 | $485.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2025-03-30 to 2025-06-28 | $50.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2024-12-29 to 2025-06-28 | $102.6m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2025-03-30 to 2025-06-28 | $185.7m | us-gaap:GrossProfit |
| Gross profit | 6 months2024-12-29 to 2025-06-28 | $382.8m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2025-03-30 to 2025-06-28 | $81.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2024-12-29 to 2025-06-28 | $173.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2025-03-30 to 2025-06-28 | $16.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-12-29 to 2025-06-28 | $32.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-03-30 to 2025-06-28 | $259.0k | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2024-12-29 to 2025-06-28 | $670.0k | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2025-03-30 to 2025-06-28 | $8.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-12-29 to 2025-06-28 | $15.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-03-30 to 2025-06-28 | $9.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-12-29 to 2025-06-28 | $19.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-03-30 to 2025-06-28 | $0.52 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-12-29 to 2025-06-28 | $1.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-03-30 to 2025-06-28 | $0.52 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-12-29 to 2025-06-28 | $1.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-03-30 to 2025-06-28 | 18,536,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-12-29 to 2025-06-28 | 18,811,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-12-29 to 2025-06-28 | $27.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-12-29 to 2025-06-28 | $7.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2024-12-29 to 2025-06-28 | $27.5m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2025-06-28 | $151.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-28 | $261.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-28 | $734.5m | us-gaap:Assets |
| Current liabilities | At period end2025-06-28 | $121.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-28 | $149.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-06-28 | $531.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000896264-25-000205. Last ingested by Listed: Nov 3, 2026, 19:18 ET. Listed shows no prices and gives no investment advice.